Boston Scientific moves & recall
Boston Scientific bolstered its EMEA urology footprint with acquisitions like Axonics and Valencia Technologies while simultaneously expanding a recall of Accolade pacemakers to about 1.6 million devices due to software risks — a growth-and-risk one-two punch. The deal activity aims to reshape its valuation story even as the recall keeps post‑market surveillance squarely in focus. (simplywall.st, simplywall.st)
Boston Scientific closed the Axonics transaction on Nov. 15, 2024 at $71 per share, valuing the deal at roughly $3.7 billion in equity and about $3.3 billion in enterprise value. (news.bostonscientific.com) The company announced a definitive agreement to buy Valencia Technologies on Jan. 12, 2026, acquiring the eCoin implantable tibial‑nerve‑stimulation system that received FDA clearance in 2022. (prnewswire.com) Boston Scientific executives have quantified the strategic lift from these buys, saying Axonics’ sacral neuromodulation portfolio raises treated‑patient reach in EMEA from roughly one million to more than three million patients. (medicaldevice-network.com) Company filings and press materials in mid‑March 2026 expanded the Accolade advisory to include all CRT‑P and DR‑EL models, bringing the advisory population to about 1.6 million devices worldwide. (nytimes.com) Reporting based on internal documents says Boston Scientific tests in 2025 identified batteries with an “extremely high failure rate,” a finding cited in coverage of the expanding Accolade actions. (nytimes.com) Boston Scientific’s March advisory describes Brady SMR6 as mitigating unintended behaviors from earlier updates and confirms the company is developing a software patch to detect high‑impedance battery states and push alerts through the LATITUDE programmer. (bostonscientific.com) Market response has been mixed: Needham reiterated a Buy rating with a $97 target after the recall amendment, while company guidance for the Axonics acquisition said the transaction would be immaterial to adjusted EPS in 2024–25 and accretive thereafter. (marketbeat.com)
